XT
EPRX

XTX Topco’s Eupraxia Pharmaceuticals EPRX Stock Holding History

XTX Topco’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$464K Buy
+70,265
New +$484K 0.01% 2533
2026
Q1 		– Sell
-16,180
Closed -$122K – 4496
2025
Q4 		$122K Buy
+16,180
New +$99.7K ﹤0.01% 2582

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

XTX Topco's EPRX Position: Q2 2026 in Review

XTX Topco opened a new position in Eupraxia Pharmaceuticals (EPRX) in Q2 2026: 70,265 shares worth $464K. The stake represents 0.01% of the portfolio and ranks #2533 among its holdings. This is a return to the name: XTX Topco previously reported a position in EPRX as recently as Q4 2025.

XTX Topco first reported a position in EPRX in Q4 2025 and has held it in 2 quarters since. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • XTX Topco held 70,265 shares of Eupraxia Pharmaceuticals worth $464K as of Q2 2026.
  • Eupraxia Pharmaceuticals was a new XTX Topco position in Q2 2026.
  • Eupraxia Pharmaceuticals made up 0.01% of XTX Topco's portfolio in Q2 2026, its #2533 holding.
  • XTX Topco first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.